Effects of V.II-BE on the number of circulating virus particles and immune cells in the blood in patients diagnosed positive with HIV

Completed

• Conditions: Infections and Infestations; HIV at a stage where antiviral treatment is not yet recommended according to medical guidelines; Human immunodeficiency virus [HIV] disease

• Registration Number: ISRCTN83581730
• Lead Sponsor: GHS AG (Liechtenstein)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-10-08
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Patients up to the age of 50 diagnosed with an HIV infection
2. Virus load below 50,000 copies/ml of blood
3. CD4 cell count above 350 cells/µl of blood
4. Stable virus load for the past 6 months

Exclusion Criteria

Patients cannot be included if:
1. They receive antiviral medication
2. They are treated with antibiotics
3. They undergo chemotherapy for cancer treatment
4. They have a background of abusing alcohol or illicit drugs
5. They have a co-infection with hepatitis
6. They are, in the case of women, pregnant or lactating

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Virus load and CD4 cell count

Secondary Outcome Measures

Name	Time	Method
Safety laboratory values